Corient Private Wealth
RLMD icon

Corient Private Wealth’s Relmada Therapeutics RLMD Stock Holding History

Corient Private Wealth’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.96M Sell
719,582
-719,582
-50% -$3.4M 0.01% 844
2025
Q4 		$6.89M Buy
1,439,164
+1,232,497
+596% +$4.13M ﹤0.01% 916
2025
Q3 		$402K Hold
206,667
– – ﹤0.01% 1935
2025
Q2 		$120K Buy
+206,667
New +$106K ﹤0.01% 2308

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Corient Private Wealth's RLMD Position: Q1 2026 in Review

Corient Private Wealth reduced its Relmada Therapeutics (RLMD) stake by 50% in Q1 2026, selling an estimated $3.4M and leaving 719,582 shares worth $4.96M. The position accounts for 0.01% of the portfolio, ranked #844.

Corient Private Wealth first reported a position in RLMD in Q2 2025 and has held it in 4 quarters since. The position peaked at $6.89M in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Corient Private Wealth held 719,582 shares of Relmada Therapeutics worth $4.96M as of Q1 2026.
  • Corient Private Wealth sold 719,582 Relmada Therapeutics shares in Q1 2026, an estimated $3.4M.
  • Relmada Therapeutics made up 0.01% of Corient Private Wealth's portfolio in Q1 2026, its #844 holding.
  • Corient Private Wealth first reported a position in Relmada Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Corient Private Wealth's Relmada Therapeutics position peaked at $6.89M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.